What is Hemanext?
Hemanext is a Massachusetts-based medical technology company focused on developing and manufacturing advanced devices for the processing and storage of eligible red blood cells. This technology aims to enhance the efficiency and safety of blood management within healthcare systems. The company's commitment to innovation in this critical area positions it as a key player in the medtech sector, addressing persistent challenges in blood preservation and utilization.
How much funding has Hemanext raised?
Hemanext has raised a total of $130.9M across 10 funding rounds:
Private Equity
$12.3M
Private Equity
$2.7M
Debt
$2M
Debt
$350K
Series A
$15M
Series B
$18M
Multiple Rounds
$80.6M
Private Equity (2011): $12.3M, investors not publicly disclosed
Private Equity (2017): $2.7M, investors not publicly disclosed
Debt (2018): $2M, investors not publicly disclosed
Debt (2020): $350K featuring PPP
Series A (2021): $15M backed by Antaeus Wealth Advisors
Series B (2022): $18M, investors not publicly disclosed
Private Equity (2025): $20M, investors not publicly disclosed
Stock/Share Issuance (2025): $18.9M, investors not publicly disclosed
Private Equity (2025): $21.7M, investors not publicly disclosed
Private Equity (2025): $20M, investors not publicly disclosed
Key Investors in Hemanext
Antaeus Wealth Advisors
Antaeus Wealth Advisors is an integrated investment and financial planning firm based in Boxborough, Massachusetts, providing customized financial advice and guiding clients through market and life cycles. They focus on trust, integrity, and prosperity, putting client interests first.
What's next for Hemanext?
With the recent influx of capital, Hemanext is poised for accelerated growth and further development of its proprietary technology. The enterprise-level investment suggests a strategic focus on scaling operations, expanding market reach, and potentially advancing clinical applications. This financial backing will likely enable Hemanext to enhance its manufacturing capabilities, invest in research and development, and strengthen its position in the competitive medical device industry. The company's trajectory indicates a move towards broader adoption and impact in transfusion medicine.
See full Hemanext company page
